{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:51:49Z","timestamp":1789167109319,"version":"build-2803163510"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118211","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:08:16Z","timestamp":1783008496000},"page":"118211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MAPK-driven remodeling of mitochondrial dynamics in melanoma: implications for metabolic plasticity and response to targeted therapy"],"prefix":"10.1016","volume":"252","author":[{"given":"L.F.L.","family":"Prado-Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Grabauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chaguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.Y.","family":"Urushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.R.","family":"Mangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.S.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-0224","authenticated-orcid":false,"given":"T.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118211_b0005","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","article-title":"Updating the Definition of Cancer","volume":"21","author":"Brown","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118211_b0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118211_b0020","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118211_b0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","article-title":"Targeted Therapy and Immunotherapy in Melanoma","volume":"41","author":"Lazaroff","year":"2023","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.bcp.2026.118211_b0030","doi-asserted-by":"crossref","DOI":"10.1177\/1534735421990078","article-title":"Current Advancements and Novel strategies in the Treatment of Metastatic Melanoma","volume":"20","author":"Sood","year":"2021","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118211_b0035","doi-asserted-by":"crossref","unstructured":"S. Shen, J. Clairambault, Cell plasticity in cancer cell populations, F1000Res 9 (2020) F1000 Faculty Rev-635. https:\/\/doi.org\/10.12688\/f1000research.24803.1.","DOI":"10.12688\/f1000research.24803.1"},{"key":"10.1016\/j.bcp.2026.118211_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102995","article-title":"Metabolic rewiring in melanoma drug-resistant cells","author":"Bristot","year":"2020","journal-title":"Critical Reviews in Oncology\/hematology 153"},{"key":"10.1016\/j.bcp.2026.118211_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bcp.2026.118211_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.849962","article-title":"Mitochondrial Fission and Fusion in Tumor Progression to Metastasis","volume":"10","author":"Boulton","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0055","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3389\/fonc.2020.00722","article-title":"Metabolic Plasticity of Melanoma Cells and their Crosstalk with Tumor Microenvironment","volume":"10","author":"Avagliano","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118211_b0060","unstructured":"I. Herskowitz, MAP Kinase Pathways in Yeast: For Mating and More Review, (n.d.)."},{"key":"10.1016\/j.bcp.2026.118211_b0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/excr.1999.4687","article-title":"New Insights into the Control of MAP Kinase Pathways","volume":"253","author":"English","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2026.118211_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and their regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and Function of the MAPKs and their Substrates, the MAPK-Activated Protein Kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.bcp.2026.118211_b0080","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates their activity in BRAFV600E Melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0085","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.1038\/sj.onc.1207185","article-title":"Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf","volume":"22","author":"Brummer","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118211_b0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20082234","article-title":"Dual-specificity phosphatases: critical regulators with diverse cellular targets","author":"Patterson","year":"2009","journal-title":"Biochemical Journal 418"},{"key":"10.1016\/j.bcp.2026.118211_b0095","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1083\/jcb.122.5.1079","article-title":"Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts","volume":"122","author":"Lenormand","year":"1993","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0100","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118211_b0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0092-8674(00)81189-7","article-title":"Phosphorylation of the MAP Kinase ERK2 Promotes its Homodimerization and Nuclear Translocation","volume":"93","author":"Khokhlatchev","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0110","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cub.2006.04.044","article-title":"Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 phase to allow Cell-Cycle Progression","volume":"16","author":"Yamamoto","year":"2006","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1385\/MB:31:2:151","article-title":"The ERK Cascade: a Prototype of MAPK Signaling","volume":"31","author":"Rubinfeld","year":"2005","journal-title":"MB"},{"key":"10.1016\/j.bcp.2026.118211_b0120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1947601911411084","article-title":"Ras in Cancer and Developmental Diseases","volume":"2","author":"Fernandez-Medarde","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bcp.2026.118211_b0125","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118211_b0130","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: what do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.118211_b0135","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118211_b0140","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118211_b0145","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","article-title":"Melanoma: from mutations to medicine","volume":"26","author":"Tsao","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2026.118211_b0150","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bcp.2026.118211_b0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118211_b0160","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118211_b0165","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-14-0729","article-title":"Mutation-specific RAS Oncogenicity explains NRAS Codon 61 selection in Melanoma","volume":"4","author":"Burd","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118211_b0170","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118211_b0175","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","article-title":"The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma","volume":"19","author":"Sheppard","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118211_b0180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bcp.2026.118211_b0185","first-page":"172","volume":"23","author":"Chiappetta","year":"2015","journal-title":"Di Cristofano, BRAF and NRAS Mutations Are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma, Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.bcp.2026.118211_b0190","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/sj.onc.1209379","article-title":"Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma","volume":"25","author":"Sensi","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118211_b0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21037\/acr-23-83","article-title":"Concomitant BRAF V600E and NRAS Q61R mutations in the same thyroid nodule: a case report","volume":"8","author":"Brogna","year":"2024","journal-title":"AME Case Rep"},{"key":"10.1016\/j.bcp.2026.118211_b0200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.humpath.2018.11.014","article-title":"Clinical validation of coexisting driver mutations in colorectal cancers","volume":"86","author":"Zheng","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bcp.2026.118211_b0205","doi-asserted-by":"crossref","first-page":"77163","DOI":"10.18632\/oncotarget.12848","article-title":"Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance","volume":"7","author":"Raaijmakers","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118211_b0210","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118211_b0215","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118211_b0220","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118211_b0225","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118211_b0230","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118211_b0235","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118211_b0240","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118211_b0245","first-page":"358","article-title":"Discovery of Dabrafenib: a Selective Inhibitor of Raf Kinases with Antitumor activity against B-Raf-Driven Tumors, ACS Med","volume":"4","author":"Rheault","year":"2013","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bcp.2026.118211_b0250","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/14796694.2026.2643481","article-title":"Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma","volume":"22","author":"Dummer","year":"2026","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2026.118211_b0255","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118211_b0260","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40265-016-0562-7","article-title":"Cobimetinib Plus Vemurafenib: a Review in BRAF (V600) Mutation-positive Unresectable or Metastatic Melanoma","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2026.118211_b0265","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1060028016672037","article-title":"A Novel MEK Inhibitor for Metastatic Melanoma","volume":"51","author":"Signorelli","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118211_b0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK and the inhibitors: from bench to bedside","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118211_b0275","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1042\/BST20140129","article-title":"Intrinsic and acquired resistance to MEK1\/2 inhibitors in cancer","volume":"42","author":"Sale","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2026.118211_b0280","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.01.008","article-title":"Mutant BRAF melanomas\u2013dependence and resistance","volume":"19","author":"Poulikakos","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0285","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118211_b0290","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/pcmr.12092","article-title":"Selective RAF inhibitor impairs ERK1\/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells","volume":"26","author":"Le","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bcp.2026.118211_b0295","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/onc.2010.408","article-title":"Hyperactivation of MEK\u2013ERK1\/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells","volume":"30","author":"Kaplan","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118211_b0300","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1755-148X.2010.00763.x","article-title":"PLX4032, a potent inhibitor of the B\u2010Raf V600E oncogene, selectively inhibits V600E\u2010positive melanomas","volume":"23","author":"Lee","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bcp.2026.118211_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114104","article-title":"Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics","volume":"178","author":"Ferraz","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118211_b0310","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3390\/ijms26062675","article-title":"Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize NRAS Mutant-Melanoma to Vemurafenib","volume":"26","author":"L.F.L. do Prado-Souza, L.S. Ferraz, T. Citrangulo Tortelli, C.A.J. Ribeiro, D.T. do Amaral, D.C. Arruda, \u00c9.A. de Oliveira, R. Chammas, S.S. Maria-Engler, T. Rodrigues,","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118211_b0315","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118211_b0320","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2013.07.046","article-title":"Allosteric activation of functionally asymmetric RAF kinase dimers","volume":"154","author":"Hu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0325","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0330","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118211_b0335","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118211_b0340","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/1873-3468.12740","article-title":"A compendium of ERK targets","volume":"591","author":"\u00dcnal","year":"2017","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2026.118211_b0345","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/2767-9764.CRC-24-0036","article-title":"A phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma","volume":"4","author":"Buchbinder","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bcp.2026.118211_b0350","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41580-020-0210-7","article-title":"The cell biology of mitochondrial membrane dynamics","volume":"21","author":"Giacomello","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0355","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.tcb.2014.08.005","article-title":"Mitochondria: from cell death executioners to regulators of cell differentiation","volume":"24","author":"Kasahara","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0360","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nrm3013","article-title":"Mitochondrial fusion and fission in cell life and death","volume":"11","author":"Westermann","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0365","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.1074\/jbc.M114.610881","article-title":"The Mechanoenzymatic Core of Dynamin-related Protein 1 Comprises the Minimal Machinery Required for Membrane Constriction*","volume":"290","author":"Francy","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118211_b0370","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41420-025-02458-0","article-title":"DRP1, fission and apoptosis","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2026.118211_b0375","doi-asserted-by":"crossref","first-page":"35967","DOI":"10.1074\/jbc.M404105200","article-title":"Intra- and intermolecular domain interactions of the C-terminal GTPase effector domain of the multimeric dynamin-like GTPase Drp1","volume":"279","author":"Zhu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118211_b0380","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1091\/mbc.e12-10-0721","article-title":"Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission","volume":"24","author":"Los\u00f3n","year":"2013","journal-title":"MBoC"},{"key":"10.1016\/j.bcp.2026.118211_b0385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41586-021-03214-x","article-title":"Function and regulation of the divisome for mitochondrial fission","volume":"590","author":"Kraus","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118211_b0390","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1091\/mbc.E15-08-0591","article-title":"The mitochondrial fission receptor Mff selectively recruits oligomerized Drp1","volume":"26","author":"Liu","year":"2015","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0395","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tcb.2020.09.008","article-title":"Mitochondrial Fusion: the Machineries In and out","volume":"31","author":"Gao","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0400","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2337\/db21-0800","article-title":"Mitofusins Mfn1 and Mfn2 are Required to Preserve Glucose- but not Incretin-Stimulated \u03b2-Cell Connectivity and Insulin Secretion","volume":"71","author":"Georgiadou","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2026.118211_b0405","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1083\/jcb.201609019","article-title":"Structures of human mitofusin 1 provide insight into mitochondrial tethering","volume":"215","author":"Qi","year":"2016","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0410","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41594-018-0034-8","article-title":"Structural basis for GTP hydrolysis and conformational change of MFN1 in mediating membrane fusion","volume":"25","author":"Yan","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0415","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tem.2022.07.003","article-title":"OPA1 regulation of mitochondrial dynamics in skeletal and cardiac muscle","volume":"33","author":"Noone","year":"2022","journal-title":"Trends in Endocrinology & Metabolism"},{"key":"10.1016\/j.bcp.2026.118211_b0420","first-page":"951","article-title":"Relationship between OPA1 and cardiolipin in mitochondrial inner-membrane fusion","volume":"2018","author":"Ban","year":"1859","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"10.1016\/j.bcp.2026.118211_b0425","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1126\/science.1219855","article-title":"Mitochondrial Fission, Fusion, and stress","volume":"337","author":"Youle","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118211_b0430","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.emboj.7601963","article-title":"Fission and selective fusion govern mitochondrial segregation and elimination by autophagy","volume":"27","author":"Twig","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2026.118211_b0435","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cmet.2013.03.002","article-title":"Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure","volume":"17","author":"Liesa","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118211_b0440","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","article-title":"Mitochondria and Cancer","volume":"166","author":"Vyas","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0445","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cmet.2014.03.011","article-title":"Proteolytic cleavage of Opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation","volume":"19","author":"Mishra","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118211_b0450","first-page":"583","article-title":"PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation, Protein","volume":"10","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0455","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/cr.2017.155","article-title":"Mitochondrial metabolism and cancer","volume":"28","author":"Porporato","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2026.118211_b0460","first-page":"798","author":"Guido","year":"2012","journal-title":"Mitochondrial Fission Induces Glycolytic Reprogramming in Cancer-Associated Myofibroblasts, Driving Stromal Lactate Production, and Early Tumor Growth Oncotarget 3"},{"key":"10.1016\/j.bcp.2026.118211_b0465","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1002\/jcb.27518","article-title":"Mitochondrial dynamic alterations regulate melanoma cell progression","volume":"120","author":"Dal Yontem","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2026.118211_b0470","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/nu17071113","article-title":"Emodin and Aloe-Emodin Reduce Cell Growth and Disrupt Metabolic Plasticity in Human Melanoma Cells","volume":"17","author":"Baldassari","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2026.118211_b0475","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1021\/acs.jmedchem.9b01098","article-title":"Exploring Mitochondria-Mediated Intrinsic Apoptosis by New Phytochemical Entities: an Explicit Observation of Cytochrome c Dynamics on Lung and Melanoma Cancer Cells","volume":"62","author":"Arya","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118211_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116307","article-title":"The interplay of p38 MAPK signaling and mitochondrial metabolism, a dynamic target in cancer and pathological contexts","author":"Sarg","year":"2024","journal-title":"Biochemical Pharmacology 225"},{"key":"10.1016\/j.bcp.2026.118211_b0485","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/pcmr.12021","article-title":"Mitophagy or how to control the Jekyll and Hyde embedded in mitochondrial metabolism: implications for melanoma progression and drug resistance","volume":"25","author":"Soengas","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bcp.2026.118211_b0490","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.tibs.2016.01.001","article-title":"Mitochondrial Cristae: where Beauty Meets Functionality","volume":"41","author":"Cogliati","year":"2016","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.bcp.2026.118211_b0495","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1007\/s10495-025-02155-4","article-title":"Mitochondrial bioenergetics and networks in melanoma: an update","volume":"30","author":"Giannitti","year":"2025","journal-title":"Apoptosis"},{"key":"10.1016\/j.bcp.2026.118211_b0500","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.3390\/cells10113197","article-title":"Mitochondrial Metabolism in Melanoma","volume":"10","author":"Huang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118211_b0505","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1038\/onc.2014.249","article-title":"Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma","volume":"34","author":"Roesch","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118211_b0510","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/pcmr.12298","article-title":"Mitochondrial dynamics regulate melanogenesis through proteasomal degradation of MITF via ROS-ERK activation","volume":"27","author":"Kim","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bcp.2026.118211_b0515","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0520","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","article-title":"PGC1\u03b1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress","volume":"23","author":"Vazquez","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0525","doi-asserted-by":"crossref","first-page":"45208","DOI":"10.1021\/acsomega.3c06547","article-title":"DRP1: At the Crossroads of Dysregulated Mitochondrial Dynamics and Altered Cell Signaling in Cancer Cells","volume":"8","author":"Adhikary","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2026.118211_b0530","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.molcel.2015.02.021","article-title":"Extracellular Regulated Kinase Phosphorylates Mitofusin 1 to Control Mitochondrial Morphology and Apoptosis","volume":"58","author":"Pyakurel","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0535","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/antiox6020033","article-title":"The Interplay between Oncogenic Signaling Networks and Mitochondrial Dynamics","volume":"6","author":"Nagdas","year":"2017","journal-title":"Antioxidants (basel)"},{"key":"10.1016\/j.bcp.2026.118211_b0540","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118211_b0545","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1712","article-title":"Targeting mitochondria metabolism for cancer therapy","volume":"11","author":"Weinberg","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118211_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.117695","article-title":"Targeting mitochondrial complexes for cancer therapy","volume":"247","author":"Osman","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118211_b0555","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118211_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2026.178800","article-title":"Targeting the energy metabolism of melanoma cells: FX-11 acts as a mitochondrial uncoupler","volume":"1022","author":"Preis","year":"2026","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118211_b0565","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10565-026-10174-3","article-title":"Mitochondrial dynamics and cancer: mechanisms and targeted therapy","volume":"42","author":"Wang","year":"2026","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.bcp.2026.118211_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114282","article-title":"Therapeutic potential of targeting mitochondrial dynamics in cancer","volume":"182","author":"Rodrigues","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118211_b0575","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molcel.2015.01.002","article-title":"Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth","volume":"57","author":"Kashatus","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0580","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.molcel.2015.01.003","article-title":"Mitochondrial Division is Requisite to RAS-Induced Transformation and Targeted by Oncogenic MAPK Pathway Inhibitors","volume":"57","author":"Serasinghe","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0585","doi-asserted-by":"crossref","first-page":"39473","DOI":"10.18632\/oncotarget.7790","article-title":"Mitochondrial oxidative phosphorylation controls cancer cell\u2019s life and death decisions upon exposure to MAPK inhibitors","volume":"7","author":"Corazao-Rozas","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118211_b0590","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jop.12855","article-title":"Expression of mitochondrial dynamics markers during melanoma progression: Comparative study of head and neck cutaneous and mucosal melanomas","volume":"48","author":"Soares","year":"2019","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.bcp.2026.118211_b0595","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.devcel.2007.11.019","article-title":"Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax\/Bak-dependent mitochondrial outer membrane permeabilization","volume":"14","author":"Cassidy-Stone","year":"2008","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0600","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.devcel.2017.02.020","article-title":"The Putative Drp1 Inhibitor mdivi-1 is a Reversible Mitochondrial complex I Inhibitor that Modulates Reactive Oxygen Species","volume":"40","author":"Bordt","year":"2017","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bcp.2026.118211_b0605","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx4562","article-title":"Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors","volume":"11","author":"Pellattiero","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2026.118211_b0610","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41419-025-07878-5","article-title":"Metastatic breast cancer cells are selectively dependent on the mitochondrial cristae-shaping protein OPA1","volume":"16","author":"Diokmetzidou","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118211_b0615","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41598-024-51427-7","article-title":"Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy","volume":"14","author":"Tarallo","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118211_b0620","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70386","article-title":"Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous Oncology","volume":"13","author":"Tan","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2026.118211_b0625","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003057","article-title":"Vemurafenib Potently Induces Endoplasmic Reticulum Stress\u2013Mediated Apoptosis in BRAFV600E Melanoma Cells","author":"Beck","year":"2013","journal-title":"Science Signaling 6"},{"key":"10.1016\/j.bcp.2026.118211_b0630","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/1535-7163.MCT-16-0068","article-title":"The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate\u2013Lactate Exchange in BRAF-Mutant Human Melanoma Cells","volume":"15","author":"Delgado-Goni","year":"2016","journal-title":"Mol. Cancer Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:14:53Z","timestamp":1786652093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226005502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":126,"alternative-id":["S0006295226005502"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118211","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAPK-driven remodeling of mitochondrial dynamics in melanoma: implications for metabolic plasticity and response to targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118211"}}